Macrophage Migration Inhibitory Factor (MIF) Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study
| Autor: | Tim-Philipp Simon, Lara Stiehler, Lukas Martin, Josefin Soppert, Christian Bleilevens, Jürgen Bernhagen, Gernot Marx, Adrian Hoffmann, Thomas Breuer, Michael Dreher, Christian Stoppe |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
ARDS Macrophage Migration Inhibitory Factor (MIF) Clinical Biochemistry Disease 030204 cardiovascular system & hematology Gastroenterology Article law.invention 03 medical and health sciences 0302 clinical medicine law Internal medicine acute respiratory distress syndrome (ARDS) SOFA Score Medicine 030212 general & internal medicine ddc:610 ICU treatment lcsh:R5-920 business.industry acute respiratory distress syndrome (ARDS) COVID-19 medicine.disease Comorbidity Intensive care unit Macrophage Migration Inhibitory Factor (MIF) COVID-19 Biomarker (medicine) Horowitz Quotient Observational study SOFA score Macrophage migration inhibitory factor business lcsh:Medicine (General) SOFA Score |
| Zdroj: | Diagnostics Volume 11 Issue 2 Diagnostics : open access journal 11(2), 332 (2021). doi:10.3390/diagnostics11020332 special issue: "Pathology and molecular diagnostics / section board: Stephen Assinder [und zahlreiche weitere]" Diagnostics, Vol 11, Iss 332, p 332 (2021) |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics11020332 |
| Popis: | Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observational study evaluates the predictive potential of MIF for the clinical outcome after severe COVID-19 infection. Plasma MIF concentrations were measured in 36 mechanically ventilated COVID-19 patients over three days after intensive care unit (ICU) admission. Increased compared to decreased MIF was significantly associated with aggravated organ function and a significantly lower 28-day survival (sequential organ failure assessment (SOFA) score 8.2 ± 4.5 to 14.3 ± 3, p = 0.009 vs. 8.9 ± 1.9 to 12 ± 2, p = 0.296 survival: 56% vs 93% p = 0.003). Arterial hypertension was the predominant comorbidity in 85% of patients with increasing MIF concentrations (vs. decreasing MIF: 39% p = 0.015). Without reaching significance, more patients with decreasing MIF were able to improve their ARDS status (p = 0.142). The identified association between an early MIF response, aggravation of organ function and 28-day survival may open future perspectives for biomarker-based diagnostic approaches for ICU management of COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|